A nurse prepares a booster dose of the Oxford-AstraZeneca Covid-19 vaccine during a vaccination drive for people over 60, in Mexicali, Mexico, on January 3. Fast-tracked regulatory approval and the ability to run clinical trials concurrently helped ensure the vaccine was developed for use within a year. Photo: Reuters
A nurse prepares a booster dose of the Oxford-AstraZeneca Covid-19 vaccine during a vaccination drive for people over 60, in Mexicali, Mexico, on January 3. Fast-tracked regulatory approval and the ability to run clinical trials concurrently helped ensure the vaccine was developed for use within a year. Photo: Reuters
Kenny Shui
Opinion

Opinion

Kenny Shui and Arthur Tsang

Tale of two vaccines: AstraZeneca’s road to success offers lessons for Hong Kong’s biotech ambitions

  • An HKU team was one of the first to come up with a potential vaccine, but its bumpy development process makes one thing clear: Hong Kong has the talent but not the ecosystem to bring biotechnological breakthroughs to market

A nurse prepares a booster dose of the Oxford-AstraZeneca Covid-19 vaccine during a vaccination drive for people over 60, in Mexicali, Mexico, on January 3. Fast-tracked regulatory approval and the ability to run clinical trials concurrently helped ensure the vaccine was developed for use within a year. Photo: Reuters
A nurse prepares a booster dose of the Oxford-AstraZeneca Covid-19 vaccine during a vaccination drive for people over 60, in Mexicali, Mexico, on January 3. Fast-tracked regulatory approval and the ability to run clinical trials concurrently helped ensure the vaccine was developed for use within a year. Photo: Reuters
READ FULL ARTICLE